Cartilage status at 30-month follow-up in subregions | Stable BMLs (n = 151; 34.3%) | Decrease of BMLs (n = 41; 9.3%) | Resolution of BMLs (n = 178; 40.5%) | Progression of BMLs (n = 70; 15.9%) | No BML at baseline and follow-up (n = 4687; 96.3%) | New BMLs (n = 182; 3.7%) |
Increase in cartilage score, n (%) | 41 (27.2) | 12 (29.3) | 50 (28.1) | 36 (51.4) | 281 (6.0) | 101 (55.5) |
Adjusted* OR of cartilage loss (95% CI) | 1.0 (Reference) | 1.2 (0.5 to 1.6) | 0.9 (0.5 to 1.6) | 2.8 (1.5 to 5.2) | 0.2 (0.1 to 0.3) | 3.5 (2.1 to 5.9) |
*Adjusted for gender, age, body mass index and Kellgren and Lawrence grade at baseline.
BML, bone marrow lesion; 95% CI, 95% confidence interval; OR, odds ratio.